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Abstract. Numerous studies have shown that amyloid- (A) modulate intracellular metabolic cascades and an intracellular
Ca2+ homeostasis and a cell surface NMDA receptor expression alteration in Alzheimer’s disease (AD). However most of
these findings have been obtained by using non-physiological A concentrations. The present study deals with the effect of
low A concentrations on cellular homeostasis. We used nerve growth factor-differentiated PC12 cells and murine cortical
neurons sequentially treated with low chronic monomeric or small oligomeric A concentrations and high acute oligomeric
A concentrations to bring out a priming effect of chronic treatment on subsequently high A concentrations-elicited cellular
response. Both cell types indeed displayed an enhanced capacity to bind oligomeric A after monomeric or small oligomeric
A application. Furthermore, the results show that monomeric A1–42 application to the cells induces an increase of the Ca2+-
response and of the membrane expression of the extrasynaptic subunit of the NMDA receptor GluN2B in PC12 cells, while
the opposite effects were observed in cultured neurons. This suggests a sequential interaction of A with the cellular plasma
membrane involving monomers or small A oligomers which would facilitate the binding of the deleterious high molecular A
oligomers. This mechanism would explain the slow progression of AD in the human nervous system and the deep gradient of
neuronal death observed around the amyloid plaques in the nervous tissue.
Keywords: Alzheimer’s disease, amyloid-, cortical neurons, homeostasis, in vitro model, intracellular calcium, NMDA receptor,
oligomers, pathogenesis, PC12 cells
INTRODUCTION
The neuropathological hallmarks of Alzheimer’s
disease (AD) are characterized by the presence of large
extracellular deposits of fibrillar amyloid- (A) [1–3]
and intraneuronal neurofibrillary tangles [4–6]. How-
ever, different observations suggest that fibrillar A
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may not be the primary toxic assembly state responsi-
ble for AD pathogenesis. Several groups have reported
that individuals with normal cognitive function have
A plaque loads that either meet or exceed the crite-
ria for AD diagnosis [7]. Studies have also revealed
a positive correlation between soluble A levels and
the severity of dementia [8, 9], further suggesting a
key role for soluble oligomers species in AD. In vitro
studies have reported that not only soluble oligomers
and protofibrils are toxic to neuronal cells [10], but that
they are more toxic than fibrils [11, 12].
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Considering the progression of AD, the mode of
exposure of nerve cells to amyloid- (A) peptides
seems to be very important. The question remains
whether low soluble A concentrations induce a
change in nerve cells. The initial events probably
involve the interaction of soluble oligomers with neu-
ronal membranes [13]. But AD evolves over decades in
human, while most in vitro experiments are performed
within minutes or hours. Similarly, in most biochem-
ical or electrophysiological experiments designed to
decipher the mode of action of A, the used concen-
trations are not physiological.
In an attempt to address this question we used PC12
cells, a cell line which displays a neuronal phenotype
when cultivated in the presence of nerve growth fac-
tor and primary cultures of mouse cortical neurons.
We show that these cells have an increased capacity to
bind A oligomers after pre-incubation with nanomo-
lar concentrations of soluble A1–42 and that the toxic
effect of oligomers at micromolar concentrations is
enhanced. Moreover, we also show that cell exposure
to high concentrations of A1–42 oligomers rapidly
induces changes in the membrane expression of the
GluN2B subunit of the NMDA receptor. These obser-
vations may partly explain the slow progression of the
disease in the human brain.
MATERIALS AND METHODS
Cell culture
PC12 cells (rat pheochromocytoma) were cultured
in RPMI 1640 medium supplemented with 5% heat-
inactivated horse serum, 10% fetal bovine serum
and antibiotics (penicillin 100 U/ml, streptomycin
100 U/ml) at 37◦C in 5% CO2. PC12 cells were
reseeded once a week. Before use, cells were plated
in 35 mm glass-bottom culture dishes coated with rat
tail type I collagen (0.1 mg/ml) and Poly-L-ornithine
(0.5 mg/ml) and NGF (50g/l) was added in the cul-
ture medium to induce their neuronal differentiation.
Cells were used after 5 days in vitro.
Except for rat tail type I collagen and poly-L-
ornithine which were supplied by Sigma-Aldrich
(Sigma, St. Louis, MO) all products used to cultivate
PC12 cells were supplied by Life Technologies® (St
Aubin, France).
Primary neuronal cultures were prepared from
C57Bl6-OF1 mouse embryos (E16-E18). Preg-
nant females were from Charles River (L’Abresle,
France) or from Chronobiotron-CNRS (Strasbourg,
France). Cortices were dissociated in a trypsin-EDTA
enzymatic solution (0.05%, Life Technologies) for
2 min at 37◦C. The dissociation was then mechani-
cally completed in Neurobasal medium supplemented
with B27 (2%), glutamax (1%), and antibiotics
(streptomycine 100 U/mL, penicillin 100 U/mL).
After centrifugation (500 g, 5 min), the pellet was
resuspended in Neurobasal medium and seeded on
glass-bottom culture dishes (Corning, Avon, France).
The cultures were kept at 37◦C under 5 % CO2 atmo-
sphere during 9 to 14 days with a partial medium
renewal every 2 days.
Preparation of amyloid peptide monomers,
oligomers
A1–42 (Bachem, Bubendorf, Switzerland) was
dissolved in hexafluoroisopropanol (HFIP; Sigma-
Aldrich), distributed in aliquots, dried (HFIP film)
and stored at −80◦C as previously described [14,
15]. The day before the experiment the peptide film
was dissolved (1 mM) in sterile dimethylsulfoxide
(DMSO). The solution was then diluted with phos-
phate buffered saline (PBS, pH 7.4) at a final nominal
concentration of 100M and aged overnight at 4◦C.
The preparation was centrifuged for 15 min at 14000×
g to remove insoluble aggregates (Protofibrils and fib-
rils) and the supernatant containing soluble A1–42
oligomers was transferred to new tubes and stored at
4◦C. The “monomer” solutions were used immediately
after dissolution in DMSO.
We measured A1–42 concentrations in the stock
solution with a classical method (Bradford). However
in the experimental conditions of cell pre-treatment,
the A1–42 solution was applied within the culture
medium, which introduces measurement bias. We thus
used an ELISA kit specifically developed for A1–42
(BetaMark-x42, Eurogentec, San Diego, CA USA). In
this case, the actual final concentration measured was
between 2 and 4 nM for a nominal concentration of
10 nM. For this reason, the nominal concentration is
systematically quoted, knowing that the final concen-
tration is probably less.
Aβ peptidic treatment
The A1–42 and the A42–1 synthetic peptides
(Bachem) were first dissolved in DMSO (Sigma) and
then diluted in the working media. According to exper-
imental conditions, two types of peptidic treatments
have been applied on the cells. For “chronic” treat-
ment, cells were maintained at 37◦C in 5% CO2 and the
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Fig. 1. Biochemical characterization of A1–42 applied solutions.
SDS-PAGE separation followed by western blot revealed with 6E10
antibody shows that the RPMI solution of A1–42 at low concentra-
tion (10 nM) contains a mixture of monomers (4.3 kD) and higher
molecular weight oligomers (68 kD), while at high concentration
(1M) the A42 preparation mostly contains high molecular weight
oligomers (60–68 kD and 140 kD).
treatment consisted of an overnight application of pep-
tide A1–42 or A42–1 (10 nM nominal). For “acute”
application, A1–42 or the reverse peptide A42–1
were diluted in phosphate buffered saline (PBS)
for immunochemistry or Hepes buffer (D–Glucose
5.5 mM, MgCl2 1 mM, CaCl2 2 mM, NaCl 130 mM,
KCl 5.4 mM, Hepes 10 mM, pH 7.4) buffer for calcium
imaging and then applied to the cells at a final con-
centration of 1M. To quantify the binding of A1–42
oligomers to the cells (see following section), this solu-
tion was applied at 200 nM final concentration.
Immunocytochemistry
In a first double immunolabeling experiments
(Figs. 2 and 3), cells were acutely treated ([A1–42
or the reverse A42–1] = 1M diluted in PBS, for
10 min). Cells were subsequently rinsed to eliminate
unbound A and fixed with 4% paraformaldehyde
in PBS for 10 min. Cells were then incubated in
a blocking solution (3% BSA in PBS) for 1 h at
room temperature. Fixed and non-permeabilized PC12
cells were first incubated with Alexa Fluor 488-
conjugated cholera toxin subunit B (1 : 500, Life
Technologies) for 30 min at room temperature, then
washed and incubated overnight with a primary anti-
body directed against every forms of A (6E10,
mouse monoclonal, 1 : 1000, Covance Inc., Rueil-
Malmaison, France). Cells were washed 3 × 10 min
with the blocking solution and incubated with the
appropriate secondary Dylight 549-conjugated Goat
Fig. 2. A1–42 partially co-localizes with cholera toxin on the sur-
face of PC12 cells. A1–42 immunochemical detection on PC12
cells. Cells were incubated with either 1M A42–1 (the reverse
peptide as a control condition) or with 1M A42 (Ac A1–42)
prior to fixation and immunolabeling for A1–42 (red) and cholera
toxin (green). A1–42 as revealed by the monoclonal antibody 6E10
(directed against every form of the peptide) partially colocalized with
membrane microdomains revealed by cholera toxin as quantified by
a Pearson coefficient of 0.23 ± 0.03. Calibration bar 20m.
anti-mouse IgG (1 : 1000, Jackson ImmnunoResearch
Laboratories Inc., West Grove, PA, USA). Glass slides
were mounted in Mowiol and observed with a Nikon
DIAPHOT–TMD inverted fluorescence microscope
and images were acquired with a digital camera
(DXM1200, Nikon) and the Metamorph software
(Molecular Devices).
In experiments aimed at quantifying the binding
of A1–42 oligomers (Figs. 6 and 7) the cells have
undergone a chronic treatment ([A1–42 or the reverse
A42–1] = 10 nM diluted in culture media overnight)
and/or an acute treatment with 200 nM A1–42
oligomer solution or with 200 nM A42–1 in order to
avoid micrograph light saturation. A rabbit polyclonal
antibody A11 directed against A oligomers (Chemi-
con International, Temecula, CA; diluted 1 : 1500 in
blocking solution) was applied to the cells overnight
at 4◦C. Cells were washed three times for 10 min
with the blocking solution and incubated with the
appropriate secondary alexa 546-conjugated antibody
(1 : 2000, Life Technologies) for 2 h at room temper-
ature, washed 3 × 10 min in PBS. In this case fixed
primary cultured neurons were also incubated with
an anti MAP2 primary antibody (chicken polyclonal,
1 : 5000, Thermo Scientific) and with an anti-GFAP
antibody (rabbit polyclonal, 1 : 5000, Dako, Denmark)
and revealed with secondary antibodies (Dylight.649
goat anti chicken IgY, 1 : 1000 and Dylight 488 anti
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Fig. 3. A42 binds and partially colocalizes with Thy1 on the sur-
face of cultured neurons. A1–42 immunochemical detection on
cultured mouse cortical neurons. Cells were incubated either with
1M A1–42 or with 1M Ab42–1 as a control or with the vehicle
solution prior to fixation. A1–42 was revealed by the 6E10 mono-
clonal antibody (green) and two other neuronal markers were used to
characterize the neuronal phenotype of the cells: Thy-1 (red), which
is a membrane marker, and MAP2 (blue), a cytoplasmic marker. No
A label was detected in control conditions (vehicle solution applied
to the cells). Calibration bar 20m.
rabbit IgG, 1 : 1000; Jackson ImmnunoResearch Lab-
oratories Inc.).
For GluN2B quantification experiments, cells were
incubated with an antibody directed against the
GluN2B subunit (Rabbit polyclonal, 1 : 500, Abcam,
Bristol, UK). The immunoreactivity was then revealed
by incubating the preparation with Dylight 488-
conjugated Goat anti-rabbit IgG antibodies (1 : 1000,
Jackson ImmnunoResearch Laboratories Inc.) for 2 h
at room temperature, washed 3 × 10 min in PBS and
mounted in Mowiol.
In some experiments, fixed neurons were also
incubated with an anti-Thy-1.2 primary antibody
(rat monoclonal, 1 : 1000; Pharmingen, San Diego,
USA) and revealed with Dylight 549-conjugated Goat
anti-rat IgG (1 : 1000, Jackson ImmnunoResearch
Laboratories Inc.).
For quantitative imaging, the micrograph record
was performed on a Carl Zeiss LSM 510 confocal
microscope (Munich, Germany). Images were subse-
quently processed with Image J software (NIH) for
quantification and the Pearson coefficient was calcu-
lated to assess for the co-localization of the markers.
Calcium imaging
Fura-2 AM dissolved in DMSO (100M) and
Pluronic F-127 (16M dissolved in DMSO, Life Tech-
nologies) were mixed (1/1 v) and added to cells platted
on glass–bottom culture dishes in a Hepes buffer for
20 min at 37◦C (1M Fura-2 final concentration).
Cells were washed 3 times and again incubated in
Hepes buffer for 20 min at 37◦C to ensure the com-
plete probe hydrolysis. Cells were maintained in Hepes
buffer during image acquisition. Data were acquired
with an Axiovert 135 microscope (Carl Zeiss), an
IMAGE-CDD digital camera (Hamamatsu photonics)
and the MetaFluor software (Molecular Devices). Flu-
orescence was excited by a xenon lamp equipped with
two alternating filters allowing a fluorescence excita-
tion at 350 nm for Ca2+-bound Fura-2 and at 380 nm
for unbound Fura-2. Emitted fluorescence intensities
(510 nm) were measured from regions of interest cen-
tered on individual cells. A pair of images was captured
every five seconds. Normalized ratio were calculated
by dividing all ratio between fluorescence intensi-
ties emitted when cells were excited at 350 nm and
when cells were excited at 380 nm by the mean of
this ratio during baseline time (F 350/F 380)/mean (F
350/F 380). Variations of these normalized ratio reflect
[Ca2+]i changes.
Cells were pretreated with A1–42 or reverse
A42–1 (10 nM) overnight when required. A1–42
(1M final concentration), reverse A42–1 (1M)
were dissolved in Hepes buffer and added to the
extracellular medium about 3 min after starting the
recording. When required, N-methyl-D-aspartate
receptor (NMDAR) antagonists were added to
the extracellular medium just before starting the
acquisition.
Western blots
To characterize the proportions of A monomers
and oligomers in the solutions applied on cells, chronic
and acute solutions were prepared by diluting A1–42
in RPMI medium (50 nM) or in PBS (1M). Sam-
ples were diluted in a reducing sample buffer (TrisHCl
63 mM, glycerol 30%, SDS 2%, Bromophenol blue
0.00025%, pH 6.8) and electrophoretically separated
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by SDS-PAGE using 4–20% Tris-Glycine polyacry-
lamide gels and Novex Tris Glycin running buffer
(Life Technologies) at 125 mV for 1 h 40 min. The
gels were transferred to nitrocellulose membranes (1 h
15 min at 125 mA) in transfer buffer (Tris 25 mM,
Glycine 192 mM, SDS 0.02%, ethanol 20%). The
membranes were blocked in 0.5% nonfat dry milk
in PBS-Tween20 0.1% and incubated for 15 min with
an monoclonal anti-A 6E10 primary antibody (Cov-
ance Inc.) and an HRP-conjugated Goat anti-mouse
IgG secondary antibody (Jackson) using the SNAPi.d
system (Millipore, Molsheim, France). Final detection
was performed with chemioluminescence (Supersig-
nal west femto sensitivity substrate, Thermo Scientific)
using CL-Xposure films (Thermo Scientific).
Statistical analysis
Values are expressed as mean ± standard deviation.
The statistical significance was assessed by one way
ANOVA and subsequent Bonferroni test analysis.
RESULTS
Biochemical characterization of Aβ1–42 oligomers
Each peptide preparation applied to the cells was
evaluated for the presence of soluble oligomers by
SDS-PAGE and immunoblotting. Gels were processed
for western blotting using 6E10 monoclonal antibody,
which recognizes every form of A. Western blots
showed that preparations at low A concentrations
(nanomolar range) contained a mixture of monomers
and higher molecular weight oligomers. In prepara-
tions containing high A concentrations (micromolar
range) most of the peptide was oligomeric (Fig. 1).
Aβ interaction with the cellular membrane
To confirm that A1–42 interacts with the plasma
membrane of either differentiated PC12 cells or
cultured neurons in our experimental conditions,
multi-labelling immunochemistry experiments were
performed on cells previously incubated for 10 min in
the presence of 200nM A. A binding on PC12 cells
was revealed by using the 6E10 monoclonal antibody
and a secondary Dylight-549-conjugated antibody
associated with Alexa Fluor 488-conjugated cholera
toxin which binds to lipid microdomains [16]. As
shown in Fig. 2 A1–42 clearly labels the membrane
with a partial but consistent colocalization with cholera
toxin. The Pearson coefficient value was 0.226 ± 0.032
significantly higher than the value obtained in con-
trol conditions (0.034 ± 0.171 p < 0.05) with a reversed
A42–1 peptide.
In cultured neurons, we used an anti-MAP2 primary
antibody which is a general marker for differentiated
neurons [17] and an anti-Thy-1.2 primary antibody
which labels the neuronal plasma membrane [18].
In MAP2-positive cells, Fig. 3 shows that A1–42
partially co-localizes with Thy-1.2 (Pearson coeffi-
cient 0.192 ± 0.64). As a control we also used the
inactive reverse peptide A42–1(Pearson coefficient
0.022 ± 0.019). In this case no label was observed on
the cultured neurons similarly to cells preincubated
with the vehicle solution (Fig. 3). This observation
means that A1–42 directly interacts at least partially
with the plasma membrane of the cells in each studied
model.
Aβ triggers intracellular calcium increase
Calcium imaging experiments showed that an acute
application of A1–42 oligomers induces a rapid rise
of intracellular calcium concentration in PC12 cells
(Fig. 4A). This calcium response was dose-dependent.
When a low concentration of A1–42 (0.1M) was
applied, the calcium response developed slowly and the
amplitude was reduced but detectable; for A1–42 con-
centrations greater than or equal to 0.5M, the calcium
response was fast and large with a time-to-peak within
2 min. No response was observed following applica-
tion of the reverse peptide A42–1 suggesting a specific
effect of A1–42 (not shown). The response was rapidly
desensitizing according to a two exponential kinetics
(Fig. 4).
The effects of homogeneous monomeric and
oligomeric preparations of soluble A1–42 were
examined in fura-2-AM-loaded PC12 cells. Fig-
ure 4b illustrates the increase of intracellular free
Ca2+. Application of monomers and low molecular
weight oligomers at a final concentration of 1M
evoked no detectable change in Ca2+ concentra-
tion whereas application of the same concentration
of high molecular weight oligomers evoked a rapid
increase of [Ca2+]i. This oligomeric A-induced cal-
cium response correlates with adhesion of A1–42
oligomers on the membrane surface of PC12 cells as
revealed by immunocytochemistry with an antibody
specific for the oligomeric form of A42 (A11) (see
Fig. 6B).
A similar Ca2+-response was observed in cultured
neurons after A1–42 oligomers application (Fig. 4C):
a sharp peak and a rapid subsequent decrease of
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Fig. 4. A) A1–42-induced Ca2+ increase in PC12 cells. The effect
induced by acute application of A1–42 is dose dependent (curves are
representative of the average of 50 recorded cells; control: vehicle
application). B) Comparison of the Ca2+ response induced in PC12
cells after acute application of an A1–42 monomer solution (1M)
or of an A1–42 oligomer solution (1M) as indicated by the arrow.
The monomer solution induces a weak Ca2+ response as compared to
the oligomer-induced response. C) Comparison of the Ca2+ response
induced in cultured mouse cortical neurons after acute application
of an A1–42 monomer solution (1M) or of an A1–42 oligomer
solution (1M). No significant response was induced by monomers
application.
the intracellular [Ca2+]. As observed for PC12 cells
monomeric A1–42 applied to neurons did not evoke
any Ca2+ signal (Fig. 4C) in cultured neurons.
NMDA-R involvement in Aβ1–42 oligomer-induced
response
Since it has been shown that A1–42 toxicity
involves NMDA receptors (for a review, see [19]), we
first checked whether our models were responsive to
NMDA. Either in PC12 cells or in neurons NMDA
(100M) application induced a progressive increase
of the intracellular [Ca2+] without an initial peak in
Ca2+ concentration and without desensitization along
the duration of the recording (around 20 min); indeed
this response was completely inhibited by a previ-
ous incubation of the cells in the presence of D-APV
a non-selective antagonist of NMDA receptors (not
illustrated).
Most of the PC12 cells were not responding to
A1–42 application in the presence of 50M APV
(Table 1). In the remaining responding cells (about
5% of the total cell number), the [Ca2+]i increase
induced by A1–42 was almost completely inhibited
(94 ± 1.5%) (Table 1).
A1–42 -evoked Ca2+ response following D-APV
application was also inhibited in neurons: we observed
a partial but consistent inhibition and a decreased num-
ber of responding cells (Table 1).
Chronic incubation with low Aβ42 concentration
modulates the oligomer–induced intracellular
calcium response
To mimic physiopathological conditions, we incu-
bated PC12 cells overnight with nanomolar concentra-
tions of A1–42 or A42–1.
Acute subsequent application of A1–42 peptide
(1M; 10 min) on PC12 cells triggered a rapid rise in
intracellular calcium concentration ([Ca2+]i) (Fig. 5A)
and this response was potentiated when the cells
were preincubated with the A1–42 peptide (10 nM)
overnight or at least 16 h (chronic treatment, Fig. 5A).
The peak amplitude of the [Ca2+]i response was
significantly increased (704 ± 822 nM,n = 51, in prein-
cubated cells versus 295 ± 129 nM, n = 45, in non
preincubated cells, p < 0.01) although this value var-
ied from cell to cell. This [Ca2+]i cellular response
was specific for A1–42 application since neither acute
application of the reverse peptide A42–1 at molar
concentration nor chronic treatment with the reverse
peptide A42–1 had a significant effect on the cells
when applied (Fig. 5A). Moreover, chronic treatment
of PC12 cells with A1–42 peptide followed by acute
application of the reverse peptide A42–1 did not
induce a significant response as compared to control
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Table 1
Effect of NMDA receptor antagonist D-APV on the intracellular calcium response induced by A1–42 application to PC12 cells
Ct n = 17 A1–42 n = 21 DAPV n = 23 DAPV + A1–42 n = 21
Normalized ratio F350/F380 0.98 ± 0.02 5.18 ± 0.40∗∗∗ 1.02 ± 0.04 0.99 ± 0.03
% of responsive cells 7 ± 1.0 73.3 ± 7.6 0 9 ± 16%
% of inhibition – – – 94%±1.5
Expressed as mean ± SD; Statistical analysis of the fluorescence ratio: multifactorial ANOVA and post-hoc Bonferroni test. ∗∗∗p < 0.001 as
compared to all other conditions.
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Fig. 5. A) Chronic incubation of PC12 cells with 10 nM A1–42 concentration enhances the Ca2+ response induced by subsequent 1M A1–42
application. The inactive reverse peptide A42–1 neither induces a Ca2+ response nor modifies the A1–42 -induced response. B) Proportion of
observed responding PC12 cells (Mean ± SD). C) Chronic incubation of cultured cortical neurons with 10 nM A1–42 concentrations reduces
the Ca2+ response induced by subsequent 1M A1–42 application. D) Percentage of observed responding neurons (Mean ± SD). As observed
for PC12 cells the reverse peptide A42–1 has no effect on cortical neurons. (Statistics: one way ANOVA and subsequent Bonferroni test;
∗p < 0.05; ∗∗p < 0.01; control: vehicle application).
(Fig. 5A). This lack of effect of the reverse peptide
A42–1 was also confirmed by the weak percentage
of responding cells (Fig. 5B). It should be pointed
out that the overnight preincubation of the PC12 cells
with A1–42 did not significantly alter the number of
responsive cells (Fig. 5B). The preincubation alone
did not modified the resting [Ca2+]i (53.6 ± 10.8 nM
in control cells versus 53.4 ± 8.9 nM in preincubated
cells).
We performed this experiment with increasing con-
centrations of acutely applied A1–42 after a chronic
incubation of the cells with A1–42. This resulted in a
dose-dependent increase of the calcium signal, which
was not significantly different from the dose depen-
dence observed in cells not chronically incubated with
A1–42 (not illustrated).
Similar experiments were performed on cultured
neurons. In this case, acute application of A1–42
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(1M) following an overnight incubation of the neu-
rons in the presence of 10 nM A1–42 resulted in a
decrease of the cellular calcium response as compared
to the effect of a single acute application of the peptide
(Fig. 5C). The specificity of this effect was checked
using the reverse peptide A42–1 and no effect was
detected with the reverse peptide either on Ca2+ con-
centration (Fig. 5C) or on the number of responding
cells (Fig. 5D). Furthermore as previously observed
for PC12 cells no significant change was observed in
the basal [Ca2+]i in neurons incubated overnight with
10 nM A1–42 and then acutely treated with vehicle
(Fig. 5C).
Aβ1–42 oligomers detection in PC12 cells and
cultured neurons
Two questions arose: what was the tertiary form
of the peptide bound to the cells and responsible for
the priming effect induced on the intracellular calcium
response and was it similar in both cellular models?
To answer these points, we performed immunocyto-
chemical experiments: PC12 cells or neurons were
incubated with 200M oligomeric A1–42 with or
without preincubation with 10 nM A1–42, fixed and
then revealed with an antibody specifically directed
against A oligomers.
In PC12 cells, no significant increase of the fluores-
cent signal was observed after overnight preincubation
with 10 nM A1–42 (Fig. 6C) or after acute applica-
tion of 200M oligomeric A1–42 (Fig. 6B). When
overnight preincubation was associated to a subse-
quent acute A1–42 application, a clear signal increase
was observed (Fig. 6D, G) suggesting that most bound
A1–42 was under the oligomeric form. The quantita-
tive analysis of fluorescence intensities correlates with
the priming effect observed on the A-induced Ca2+
response: the fluorescence intensity in cells chronically
incubated with A1–42 was not significantly different
from the fluorescence measured in control cells, while
the effect of previous chronic incubation on a subse-
quent acute A1–42 application was highly significant
(p < 0.001, Fig. 6G).
In neurons, the pattern of A1–42 binding accord-
ing to the incubation conditions was similar to that
observed in PC12 cells: Fig. 7 shows a signifi-
cant increase of A1–42 immunodetection following
preincubation with 10 nM A1–42 and subsequent
application of 200 nM oligomeric A1–42.
Hence the observed opposite effect of A1–42 prein-
cubation combined with subsequent application of
high concentration on the induced Ca2+-response in
Fig. 6. Immunocytochemistry of PC12 cells revealed by the A11
antibody (oligomers specific). Cells were treated with the following
conditions: vehicle application as a control (A); acute application
of 200 nM A1–42 (B); chronic incubation of 10 nM A1–42 (C);
chronic with 10 nM A1–42 incubation followed by acute appli-
cation of 200 nM A1–42 (D); Chronic application of the reverse
peptide A42–1 (10 nM) (E); chronic incubation with 10 nM A42–1
followed by acute application of 200 nM A1–42 (F). Panel G repre-
sents the quantification of the labeling of PC12 cells under the various
conditions mentioned above. Note the increase in oligomers binding
on the cells preteated with a low A1–42 concentration (Statis-
tics: one way ANOVA and subsequent Bonferroni test; ∗∗p < 0.01;
∗∗∗p < 0.001). Calibration bar 20m.
PC12 cells and in cultured neurons was not due to a
difference in binding properties of A1–42 oligomers
following the preincubation step.
Effect of Aβ42 application on GluN2B subunit
expression.
Previous studies have reported an involvement of
the GluN2B subunit of NMDA receptor in the cellular
response induced by A1–42 application [17–21].
Since we observed that the Ca2+ response induced by
A1–42 in PC12 cells was almost completely mediated
by NMDA receptors, we checked whether the amy-
loid peptide was co-localized with NMDA receptors
on the cellular membrane. For this purpose we per-
formed double immunolabelling experiments on fixed
but non permeabilized PC12 cells. We used an antibody
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Fig. 7. Immunocytochemistry of cultured cortical neurons revealed
by the 6E10 antibody directed against A1–42. The cells were treated
with the following conditions: vehicle application as a control (A);
acute application of 200 nM A1–42 (B); chronic incubation of 10
nM A1–42 (C); chronic incubation with 10 nM A1–42 followed
by acute application of 200 nM A1–42 (D); chronic application of
the reverse peptide A42–1 (10 nM) (E); chronic incubation with
10nM A42–1 followed by acute application of 200 nM A1–42 (F).
Additional antibodies were used to distinguish neurons (anti MAP2,
blue) from astrocytes (anti GFAP, green) in the culture dish. Panel
G represents the quantification of A1–42 immunofluorescence on
neurons in the different experimental conditions. (Statistics: one way
ANOVA and subsequent Bonferroni test; ∗∗∗p < 0.001). Calibration
bar 20m.
directed against the GluN2B subunit of the NMDA
receptor and another antibody (6E10) directed against
A1–42. As illustrated in Fig. 8, we observed a partial
Fig. 8. A42 binding to PC12 cells is correlated with an increase
in the membrane expression of GluN2B. Fixed PC12 cells were
incubated with primary antibodies directed against GluN2B sub-
unit (green) and A42 (red). The chronic treatment with 10 nM
A1–42 monomers did not produce a significant increase of GluN2B
immunoreactivity. The fluorescence intensity related to GluN2B
increased when the cells were incubated with 1M oligomeric
A1–42 as illustrated by the lower panel. Note that the two antigens
are partially colocalized. However in some cells this colocaliza-
tion appears weak suggesting a heterogeneity among PC12 cells
(white arrows). (Crl: vehicle application as control; Ac: acute 1M
A application; Ch: chronic 10 nM A incubation; Statistics: one
way ANOVA and subsequent Bonferroni test; ∗p < 0.05; ∗∗p < 0.01;
∗∗∗p < 0.001). Calibration bar 20m.
co-localization of the membrane-bound A1–42 with
the GluN2B subunit. This co-localization occurred in
the presence of 10 nM monomeric A1–42 as well as
1M oligomeric A1–42 (Fig. 8).
We also observed that the fluorescence intensity
reflecting GluN2B immunoreactivity was enhanced
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in cells treated with A (Fig. 8, lower graph).
Indeed, a quantification of the fluorescence intensity
revealed no significant increase of GluN2B expression
after chronic exposure of the PC12 cells to 10 nM
monomeric A1–42. However GluN2B immunoreac-
tivity was significantly increased when the cells were
incubated with 1M oligomeric A1–42. In this case,
a trend of priming effect after chronic A1–42 applica-
tion was observed although not significant. It should be
pointed out that the cells appeared heterogeneous in the
label immuno-intensity for GluN2B (Fig. 8, arrows).
This probably reflects a partial differentiation of some
cells, and it may also explain the lack of significance
of priming effect of the cells pretreatment.
A similar experiment was performed on cultured
cortical neurons. In this case, due to the heterogene-
ity of the cellular types present in the culture it was
necessary to characterize neurons with a membranous
neuronal marker. We used double immunolabelling of
the non permeabilized cells with antibodies directed
against the GluN2B subunit and Thy1.2 respec-
tively. Several cellular types were present in the cell
culture; among these cells, some displaying a neu-
ronal morphology were expressing GluN2B but not
Thy1.2 (Fig. 9 arrows). Immunolabelling on these
cells was not quantified. On Thy1.2 positive cells we
observed a significant decrease of GluN2B expression
on the membrane after chronic application of 10 nM
monomeric A1–42 (Fig. 9). Indeed this decrease was
amplified when the cells were also subjected to acute
1M oligomeric A1–42 for 10 min.
DISCUSSION
Growing evidence points to a disruption of intra-
cellular Ca2+ homeostasis in AD and other neu-
rodegenerative diseases (for a review, see [22]),
and intracellular Ca2+ levels are known to trigger
metabolic cascades that ultimately lead to synaptic dys-
function and cell death [22, 23]. It has been established
that this deleterious effect is mainly induced by the
soluble forms of the amyloid peptides [8, 9]. However
considering the pathological and physiological con-
centrations of soluble A encountered in the nervous
tissue raises the question of such low concentrations
effects on the cellular homeostasis.
In the present report, we show that micromolar con-
centrations of A1–42 induce a transient increase of
intracellular [Ca2+] in PC12 cells expressing a neu-
ronal phenotype as well as in cultured cortical neurons.
Although the concentration used is high compared to
Fig. 9. Chronic incubation of cortical mouse neurons with 10
nM monomeric A1–42 induces a significant decrease of GluN2B
expression on the plasma membrane of the cells. Fixed non perme-
abilized cells were revealed by an anti-GluN2B primary antibody
(green) and an anti-Thy1.2 antibody (red) to characterize neurons.
The immunofluorescence of GluN2B was quantified in Thy1.2-
positive cells only (lower graph). (Crl: vehicle application as control;
Ac: acute 1M A oligomers incubation; Ch: chronic 10 nM A
monomers incubation; Statistics: one way ANOVA and subsequent
Bonferroni test; ∗∗p < 0.01; ∗∗∗p < 0.001). Calibration bar 20m.
physiological concentrations, this is in agreement with
numerous previous studies performed either on pri-
mary cultures of nerve cells or on cell lines [24–26]).
Additionally the pharmacological characterization
of the observed Ca2+ cellular response corroborates
previous observations: we show that this response
is preferentially induced by A1–42 oligomers in
agreement with other published observations [27–29].
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Prefibrillar amyloid aggregates have been shown to ele-
vate cytosolic Ca2+ in neurons or neuronal cell lines
([30, 31]), and this phenomenon has been proposed
to result from Ca2+ influx across the plasma mem-
brane either through cation-selective channels formed
by A1–42 itself or through a general disruption of
lipid integrity [12, 31, 32]. Another still controver-
sial hypothesis is based on the effect of A1–42 itself
on voltage operated calcium channels although the
peptide has been described to inhibit L-type chan-
nels at micromolar concentrations [33] and P/Q type
channels at nanomolar concentrations [34]. We cannot
exclude these hypotheses but they appear unlike since
we observed that the A1–42-induced Ca2+ response
was almost completely inhibited by APV, an antagonist
of the NMDA receptor, and Ifenprodyl, an antago-
nist specific for GluN2B subunit (not illustrated), in
both cellular models in agreement a previous observa-
tion [35].
This observation needs some comments: A1–42 has
been described to directly activate NMDA receptors
in transfected cells expressing GluN1, GluN2A, and
GluN2B subunits [36]. However one should notice
the rapid desensitization of the response induced in
PC12 cells and in neuronal cultures (see Figs. 4 and
6). By contrast [Ca2+]i is increasing without an ini-
tial peak and without desensitization upon continuous
NMDA application to PC12 cells or cultured neurons
(not illustrated). A more precise observation shows
that the decrease rate fits with a bi-exponential curve.
This means that NMDA channel activation is not the
only component involved but that a second component
is also involved in the observed response. The nature
of this process is not yet identified. In a recent study,
Kessels et al. suggest a metabotropic activity of NMDA
receptor induced by A1–42 application [37]. Another
possibility would be a massive involvement of intra-
cellular Ca2+ stores triggered by NMDA receptors as
already observed [38–40] and a delayed subsequent
enzymatic activity of the endoplasmic reticulum cal-
cium pump, which regulates Ca2+ homeostasis and
would contribute to the rapid decrease of the response.
This point has to be further elucidated.
Overnight exposure of PC12 cells to 10 nM A1–42
did not modify the basal [Ca2+]i in agreement with
previously published data [29]. Moreover we did not
observe a significant oligomeric A1–42 accumulation
on the cellular membranes after chronic exposure of
the cells as revealed by immunocytochemistry. Thus
we were not able to show any noticeable change, which
would be elicited by preincubating the cells with low
concentrations of A1–42.
There are some clues in the literature indicating that
A1–42 is acting differently depending on its cellu-
lar location or on its concentration: Puzzo et al. [42]
showed on hippocampal slices that pmolar A1–42
application was able to increase long term potentiation
while molar A1–42 application inhibited it. Acute
application of A1–42 was described to increase the
K+-induced Ca2+ response while chronic application
would induce apoptosis [29]. Additionally different
species (monomeric or oligomeric forms) of A1–42
were described to interact with cellular membranes of
PC12 cells [43]. As revealed by fluorescence measure-
ment, these different species were not exchangeable
in solution [44] and their amount binding to the
membranes depended on the peptide conformation
according to their size: low concentration would favor
monomeric or small oligomeric forms while high pep-
tide concentration triggers the binding of large soluble
oligomers [43] in agreement with our results. In our
study, however, we show a priming effect of low con-
centrations of monomeric A1–42 on the subsequent
binding of large oligomers, which suggests a functional
coupling between these two interaction modes of the
peptide with the cellular membrane. Nag et al. [43]
suggested that monomers or small oligomers bound to
the membrane would favor further aggregation of the
peptide to form large oligomers at the cellular surface.
From our results we cannot exclude such a mecha-
nism. More recently Bateman and Chakrabartty [45]
showed that monomeric A1–42 stays at the surface
of differentiated PC12 cells while large oligomers are
rapidly internalized, suggesting different properties of
these two A1–42 forms. By introducing a sequential
aspect our results corroborate and further character-
ize the A1–42 binding observed previously [43–45].
Furthermore we also demonstrate that this mode of
A1–42 interaction is also relevant for cultured cortical
neurons.
The functional consequences of the priming effect
on A1–42 binding are not even in cultured primary
neurons or in PC12 cells. Indeed the amyloid pep-
tide has been suggested to interact with extra synaptic
NMDA receptors involving GluN2B subunits [36, 46].
In mouse neurons, the primed binding of A1–42
oligomers induced a decrease in the Ca2+-response
and in the membrane expression of GluN2B. This
has been often described in the recent literature (for
a review see [48]). In PC12 cells, however, the chronic
exposure to low A1–42 concentrations induced a sig-
nificant increase of the Ca2+ response induced by a
subsequent acute application of 1M A1–42 and an
increased expression of GluN2B on the plasma mem-
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branes of the cells. Such a positive priming effect of
low A1–42 concentrations was also observed in PC12
cells by Innocent et al. [29]. In this case the K+-
induced Ca2+ response was increased. Given the rapid
effect observed (within 5 min) and the fact that it was
revealed in non permeabilized cells, this phenomenon
should not be assigned to protein synthesis but rather
to a translocation of GluN2B from the cytoplasm or
from endogenous vesicles toward the plasma mem-
brane. Is this discrepancy with cultured mouse neurons
reflecting species differences between rat PC12 cells
and murine cortical neurons? Recently Liu et al. [47]
also reported that A42 induced an increase of GluN1
and GluN2B subunits in rat hippocampal neurons in
culture, which would support this hypothesis. How-
ever numerous previous data suggested a decrease in
GluN2B after A1–42 oligomers application to rat
primary neuronal cultures or to organotypic slices
(for a review, see [48]). Several pathways regulat-
ing GluN2B including ERK/MAPK, ApoER2/reelin,
STEP61, casein kinase, or calpain activity have been
described to be involved in the toxicity of A1–42
oligomers [48]. The PC12 cell line derives from a rat
tumor and is subject to instability. Whether these regu-
lating pathways are functional in this cell line remains
to be clarified.
Hence the present study describes a functional link
between two forms of A1–42 interacting on the plasma
membrane of PC12 cells and of cultured cortical
neurons. Considering these observations we would
suggest that a low physiologic A1–42 concentra-
tion induces monomers (or small oligomers) binding
to cellular plasma membranes, which in turn favors
large oligomers to bind when the peptide concentra-
tion increases. Coming back to the physiopathology
of the disease, this could explain the deep gradient of
degenerated neurons around amyloid plaques in the
brain tissue and the slow progression of the disease.
A continuous secretion of amyloid peptides does not
notably hinder neuronal function but prepare the bad
end of the neurons. Degeneration maximally occurs in
close vicinity to senile plaques. These plaques can be
considered as A1–42 reservoirs generating high con-
centration of soluble amyloid peptide oligomers. Due
to the size of the oligomers, the diffusion of the pep-
tide through the brain tissue is limited and therefore
the concentration gradient should be high around the
amyloid plaques.
This hypothesis does not explain the spreading of
the disease throughout the brain during the course
of the pathology. It has been suggested similarities
between prion diseases and AD involving intracellu-
lar transport of misfolded particles [49, 50] before
extracellular secretion. According to this hypothesis,
monomers or small oligomers of misfolded proteins
could serve as seeds for larger pathogenic particles.
Our present observation completes this suggestion: sol-
uble misfolded A1–42 could be not only seeds for
larger oligomers, protofibrils, and ultimately plaques,
but also anchors for soluble large oligomers on cellular
membranes.
Additionally A1–42 is observed not only in CNS
but also in peripheral tissues including vessels and
blood in a number of pathologies. As an example
A1–42 is secreted by platelets in AD. It should be
of interest to determine whether this priming effect on
A1–42 oligomers binding capacity applies to a broad
variety of peripheral cell types and could serve as a
biomarker for the disease.
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